



# *Neural Diagnostics Pty Ltd*

**Objective Diagnosis of Mental Illness**

**Contact: Dr Roger Edwards      CEO**


**[roger.edwards@neuraldiagnostics.com](mailto:roger.edwards@neuraldiagnostics.com)**

**0411 193 031**



# ***EVestG™ - Electrovestibulography***

- **Objective Test for Biomarkers of Brain Function**
- **Neuro-Pharmacology Applications**
- **Diagnostic Decision Support System**



# *The Unmet Need*

US\$2 Trillion Burden of CNS Diseases Worldwide



1-in-4 will suffer from a Serious Brain-Illness



5% of Australians are treated for Depression



Reliance on Subjective Diagnostic Techniques  
leads to 25% to 40% misdiagnosed, and/or over  
12 years for final diagnosis





# ***PROGRESS***


- Main Patent lodged in Australia and China,
- Winner ABC's New Inventor's Invention of the Year 2010
- PhD Thesis on EVestG and Schizophrenia
- Commissioned first North American clinical research facility at the University of Manitoba, dementia / alzheimers study
- Awarded Commercialisation Australia P-of-C Grant
- Focus on diagnostic separation of bipolar disorder from major depression.
- Commenced Beta testing our real-time signal processing service online with Telstra [external R&D Partner]
- Completed independent Market Research on first accessible market of US Psychiatrists
- Formed strategic alliance with engineering design house

# *Market Research*

- “There are no objective tests for mental illness”
- “ Earlier diagnosis would have a profound outcome for the patient”
- “If EVestG can do what it says it will be a very valuable tool”
- Based on sample size, 90% of US Psychiatrists [30,000] would use EVestG if it were validated to objectively separate Depression from Bipolar at >80% sensitivity and specificity.
- Our results indicate we are achieving >85% accuracy

# Bipolar Disorder versus Depression

2 line separator:- BPD=88% correct, MDD 100% correct  
Accuracy 94%



# ***The Business Case***

- Cumulatively 500 Units sold with associated consumables over 5 years creates \$50m accumulated Profit.
- Globally opportunity is for over 50,000 Units
- Require \$9 Million to get first product to market over next 3 years.
- EVestG is a platform Technology suitable for many other Brain-related conditions.

# Financials as of 30 September 2011

- Market valuation N/A
- Cash raised to date \$1,800,000
- Government Grants and Tax Rebates \$2,000,000
- Runway 12 months
- Burn rate per month \$30,000
- Ownership structure 12 Angels
- Shares on issue ≈60,000,000
- Investment sought in 3 tranches \$9 million

Contact: Dr Roger Edwards – CEO - 0411 193 031  
[roger.edwards@neuraldiagnosics.com](mailto:roger.edwards@neuraldiagnosics.com)

